Company description

Triera Biosciences is a Canadian life sciences company focused on developing novel therapeutic platforms based on aptamer technology. The company aims to create faster, more cost-effective and targeted treatments for infectious diseases, immunology and oncology applications.

Triera operates as a subsidiary of Zentek Ltd., an intellectual property and advanced materials technology company. The organisation was established to commercialise proprietary aptamer-based technologies developed through collaboration with McMaster University. This partnership provides Triera with exclusive global licensing rights for aptamer and DNAzyme technologies developed within the collaboration.

The company’s technology platform focuses on synthetic DNA or RNA molecules known as aptamers, which can bind to specific biological targets similarly to antibodies but with advantages such as faster development timelines, improved consistency and lower manufacturing costs. Preclinical research conducted by Triera has demonstrated promising efficacy comparable to monoclonal antibodies across certain therapeutic applications.

Triera Biosciences is building a pipeline targeting respiratory and infectious diseases including COVID-19, influenza and other viral threats. The company is also expanding its research into broader therapeutic applications, leveraging its platform’s adaptability across multiple disease areas.

In addition to therapeutic development, recent announcements indicate that Triera is expanding into contract research organisation (CRO) services, including custom aptamer discovery, biosensor development and machine learning-based classification capabilities.

Key products and services

Aptamer therapeutic platform

• Development of synthetic aptamer-based therapeutics
• Targeted treatment discovery for infectious and immune-related diseases
• Platform technology adaptable across multiple therapeutic areas

Drug discovery and preclinical development

• Rapid candidate identification and optimisation
• Preclinical testing and validation
• Target identification and biomolecular binding technologies

Contract research services (CRO expansion)

• Custom aptamer discovery
• Biosensor enablement
• Machine learning-based classification and research support

Platform-based therapeutic development

• Respiratory and infectious disease pipeline
• Antiviral and immunology research
• Multi-target therapeutic development

Academic and research collaborations

• Exclusive partnership with McMaster University
• Access to advanced academic research infrastructure
• Joint development of next-generation therapeutics

By combining proprietary aptamer technology, academic collaboration and expanding CRO capabilities, Triera Biosciences aims to accelerate the development of targeted therapeutics and diagnostic solutions. Its platform-based approach and focus on rapid, cost-effective drug discovery position the company as an emerging innovator within the biotechnology and therapeutic development landscape.